Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
MacroGenics, Inc.
MacroGenics develops antibody-based cancer drugs and earns money by selling them and partnering with larger drugmakers.
MacroGenics is a small biotech company that designs antibody drugs for cancer. Antibodies are proteins the immune system uses to recognize and grab onto specific targets, and MacroGenics engineers its own versions to either flag cancer cells for destruction or switch immune cells on. Its medicines are given to cancer patients, mostly through hospitals and clinics, and paid for by insurers and health systems.
The company has one approved drug of its own, Margenza, a treatment for a hard-to-treat form of breast cancer. That launch has been slow and modest, because it competes in a crowded field against bigger players. Far more important financially is MacroGenics' partnership business: it licenses its antibody technology and drug candidates to larger drugmakers, which pay upfront fees and promise later payments if the drugs hit milestones and reach the market. One of its best-known inventions, margetuximab, was out-licensed and is now developed elsewhere. This partner-heavy model matters because developing a cancer drug from scratch costs hundreds of millions of dollars, money a company of MacroGenics' size simply does not have. That is also the company's core weakness. It burns cash on research and has depended on deal money, stock sales, and careful cost cuts to stay funded. When a partner reports disappointing trial results or hands a program back, the stock can move sharply, because the pipeline is the whole story. MacroGenics sits in the risky middle of biotech: too small to sell drugs at scale on its own, but with enough science to attract partners like Gilead Sciences, which has signed research deals with it.
The bet investors are making is on the pipeline rather than today's sales. If a partnered drug succeeds in late-stage trials, the milestone payments and royalties could transform the finances. If trials fail, the company must keep raising money or trim its ambitions. It is a science-first company where the next trial readout often matters more than next quarter's revenue.
Saved answer · last researched 14 Nov 2026